Journal of Immunology Research / 2013 / Article / Tab 2

Review Article

Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies

Table 2

Synopsis of broadly anti-HCV/E2 neutralizing mAbs.

mAbOriginEpitopeGenotype breadth of neutralization (HCVpp)Genotype breadth of neutralization (HCVcc)In vivo  testedEscape generationReferences

9/27RatLinear1a1a, 2aNoN.D.[3, 28, 32]
HCV-AB68HumanConformational1bN.D.YesYes[33]
AP33 (MRCT10.v362)Murine (humanized)Linear1–61a, 2aYesYes[3436]
3/11RatLinear1, 2, 4, 5, 61a, 2aNoN.D.[3, 28]
2/69aRatConformational1a, 2a1aNoN.D.[3, 28, 37]
11/20RatConformational1N.D.NoN.D.[3, 28]
1/39RatConformational1N.D.NoN.D.
H77.16MurineConformationalN.D.1aNoN.D. [38]
H77.39MurineConformationalN.D.1aNoN.D.
J6.36MurineConformationalN.D.2aNoN.D.
J6.103MurineConformationalN.D.2aNoN.D.
HCV1HumanLinear1a, 1b, 2b, 3a, 4a2aYesYes[39]
#8MurineConformationalN.D.1aNoN.D.[40, 41]
HC-1HumanConformational1a, 1b2aNoNo [42]
HC-11HumanConformationalN.D.2aNoYes
CBH-5HumanConformational1–62a, 2bNoN.D. [43, 44]
CBH-7HumanConformational1, 2, 42a, 2bNoN.D.
A8HumanConformational1–62aNoN.D. [45]
1:7HumanConformational1–62aNoN.D.
AR2AHumanConformational1a, 2a, 2b, 4, 5NoNoN.D.[46]
AR3AHumanConformational1–61–6YesN.D.[26, 46]
AR3BHumanConformational1a, 1b, 2a, 2b, 4, 52aYesN.D. [46]
AR3CHumanConformational1a, 1b, 2a, 2b, 4, 52aNoN.D.
AR3DHumanConformational1a, 1b, 2a, 2b, 4, 52aNoN.D.
AR4AHumanConformational1–61–6YesN.D. [26]
AR5AHumanConformational1a, 1b, 4, 5, 6 1a, 2a, 4, 5, 6NoND
HC33.1HumanLinearN.D.1a–6aNoN.D. [47]
HC33.4HumanLinearN.D.1a–6aNoN.D.
HC33.8HumanLinearN.D.1a, 2a, 4aNoN.D.
HC33.29HumanLinearN.D.1a, 2a, 4aNoN.D.
mu5B3 (hu5B3.v3)Murine (humanized)Linear1a, 1b, 2a2aNoYes[36]
HC84-1HumanConformational1a1a–6aNoNo [48]
HC84-27HumanConformational1a1a–6aNoNo
e20HumanConformational1a, 1b, 2a, 2b, 4, 5 (N.D. on 3 and 6)1a, 2aNoN.D.[4951]
e137HumanConformational1a, 1b, 2a, 2b, 4, 5 (N.D. on 3 and 6)1a, 2aNoN.D.[5052]

ND: not determined.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.